电影票房

您好,歡迎訪問中山大學腫瘤防治中心官方網站!
職工郵箱 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 曾木圣

    職務:中心副主任、副院長
    職稱:博士、教育部“長江學者”特聘教授、博士生導師,華南腫瘤學國家重點實驗室腫瘤病毒與生物標記研究室PI
    專長:惡性腫瘤發病機制、早期診斷和預后研究
    姓名: 曾木圣
    職稱: 博士、研究員、博士生導師、華南腫瘤學國家重點實驗室腫瘤病毒與生物標記研究室PI
    職務: 中心副主任、副院長
    專長: 惡性腫瘤發病機制、早期診斷和預后研究

      2003年回國后被中山大學腫瘤防治中心聘為副研究員,組建腫瘤病毒學和腫瘤分子標志研究組;2006年聘為研究員,博士生導師,入選2006年“教育部新世紀優秀人才計劃”; 2010入選廣東省“千百十人才國家級培養對象”,并獲得2010年“國家杰出青年科學基金”項目資助,2014年被聘為教育部“長江學者”特聘教授;2016年入選廣東省培養高層次人才特殊支持計劃“杰出人才”(南粵百杰)。現任中山大學腫瘤防治中心副主任、副院長,中國抗癌協會理事,廣東省抗癌協會第四屆理事會常務理事、秘書長,中國抗癌協會腫瘤標志專業委員會副主任委員,廣東省抗癌協會轉移委員會主任委員。

    學科:1)腫瘤學,2)生物化學與分子生物學
    專業特長:惡性腫瘤發病機制、早期診斷和預后研究
    研究方向:1. 腫瘤病毒感染、致癌及免疫調控機制
         2. 惡性腫瘤分子標志及早期診斷
         3. 分子影像及靶向治療

    聯系電話:020-87343191;(Fax):020-87342021, Email: zengmsh@sysucc.org.cn
    通訊地址:廣州市東風東路651號 中山大學腫瘤防治中心實驗研究部 郵編 510060

    【教育背景】
      1988年畢業于江西醫學院撫州分院(現南昌大學撫州醫學分院)
      1994年畢業于中山大學(原中山醫科大學),獲腫瘤學碩士學位
      1998年畢業于中山大學(原中山醫科大學),獲微生物學博士學位。

    【留學經歷】
      1999-2000年美國田納西州立大學生物系(Tennessee State University)博士后,從事維甲酸在細胞發育及分化中作用的研究
      2000-2003年美國波士頓塔夫茨大學—新英格蘭醫學中心(Tufts University-New England Medical Center)腫瘤生物學實驗室從事乳腺癌發病機理、診斷及預后指標的研究。
    姓名: 曾木圣
    職稱: 博士、研究員、博士生導師、華南腫瘤學國家重點實驗室腫瘤病毒與生物標記研究室PI
    職務: 中心副主任、副院長
    專長: 惡性腫瘤發病機制、早期診斷和預后研究

      2003年回國后被中山大學腫瘤防治中心聘為副研究員,組建腫瘤病毒學和腫瘤分子標志研究組;2006年聘為研究員,博士生導師,入選2006年“教育部新世紀優秀人才計劃”; 2010入選廣東省“千百十人才國家級培養對象”,并獲得2010年“國家杰出青年科學基金”項目資助,2014年被聘為教育部“長江學者”特聘教授;2016年入選廣東省培養高層次人才特殊支持計劃“杰出人才”(南粵百杰)。現任中山大學腫瘤防治中心副主任、副院長,中國抗癌協會理事,廣東省抗癌協會第四屆理事會常務理事、秘書長,中國抗癌協會腫瘤標志專業委員會副主任委員,廣東省抗癌協會轉移委員會主任委員。

    學科:1)腫瘤學,2)生物化學與分子生物學
    專業特長:惡性腫瘤發病機制、早期診斷和預后研究
    研究方向:1. 腫瘤病毒感染、致癌及免疫調控機制
         2. 惡性腫瘤分子標志及早期診斷
         3. 分子影像及靶向治療

    聯系電話:020-87343191;(Fax):020-87342021, Email: zengmsh@sysucc.org.cn
    通訊地址:廣州市東風東路651號 中山大學腫瘤防治中心實驗研究部 郵編 510060

    【教育背景】
      1988年畢業于江西醫學院撫州分院(現南昌大學撫州醫學分院)
      1994年畢業于中山大學(原中山醫科大學),獲腫瘤學碩士學位
      1998年畢業于中山大學(原中山醫科大學),獲微生物學博士學位。

    【留學經歷】
      1999-2000年美國田納西州立大學生物系(Tennessee State University)博士后,從事維甲酸在細胞發育及分化中作用的研究
      2000-2003年美國波士頓塔夫茨大學—新英格蘭醫學中心(Tufts University-New England Medical Center)腫瘤生物學實驗室從事乳腺癌發病機理、診斷及預后指標的研究。

    【科研成就】
      回國后組建腫瘤病毒學和腫瘤分子標志研究組,首次完成鼻咽癌相關EBV全序列分析,發現鼻咽癌相關的EBV序列特征【J Virol 2005,入選第一屆中國百篇最具影響優秀國際學術論文(科技部直屬中國科學技術信息研究所評選)】,提出并初步證實高發區NPC相關EBV亞型的假設;首次通過大樣本流行病學調查揭示吸煙可以通過激活EBV參與鼻咽癌發病的新機制;發現EBV-LMP2A通過誘導上皮間質轉化和腫瘤啟動細胞群體參與NPC發生發展的新機制;發現EBV可以誘導原癌基因Bmi-1的表達,闡明Bmi-1在鼻咽上皮細胞早期轉化和NPC侵襲和轉移中的作用,揭示PTEN/PI3K/Akt/Snail通路介導Bmi-1誘導上皮間質轉化和腫瘤轉移的新機制;并建立首個單一原癌基因誘導的鼻咽上皮細胞永生化模型和EBV高效感染上皮細胞的體外模型,鑒定出EBV感染上皮細胞的關鍵受體或因子(NRP1、MHC-IIA、EphA2等),多方面闡明EBV進入鼻咽上皮細胞的機制;近年來利用高通量測序技術深入探索頭頸腫瘤的發病機理,揭示了食管鱗狀上皮細胞癌的癌前病變的基因組特征及其與腫瘤的演化發展關系,同時首次明確了鼻咽癌和頭頸腫瘤中融合基因RARS-MAD1L1的發生率及作用機制。至2017止,作為課題主持人獲得國家自然科學基金12項(包括重點項目2項)、國家重點研發計劃、“863”課題及“973”課題各1項。發表SCI收錄論文70余篇,包括國際上具有較高影響的專業性雜志Nature Communications, Nature Microbiology, PNAS, J Clin Invest, J Natl Cancer Inst, PLoS Pathogens, Cancer Research, Clinical Cancer Research, cell research, Journal of Virology, J Biol Chem等,單篇最高IF 16.6。

    【主持的主要科研項目】
    1.國家重點研發計劃項目負責人“基于基因組不穩定性的新型蛋白質機器在腫瘤發生發展中的作用、機制及干預”2017-2022 1883萬元
    2.國家重點研發計劃子課題參與人“皰疹病毒感染與致病過程中蛋白質機器的功能機制”2016-2021 449.6萬元
    3.國家自然科學基金國際(地區)合作與交流項目,81520108022,EB病毒進入鼻咽上皮細胞受體鑒定及感染機制,2016-2020年,235萬元
    4.教育部“長江學者”特聘教授 2015-2019年 200萬元
    5.國家自然科學基金重大研究計劃(91440106)RNA結合蛋白RBM24調控miR-25-3p及lncRNA MALAT1抑制鼻咽癌的機制2015-2017年 100 萬元
    6.國家自然科學基金重點項目(81230045)融合基因AARS-MADx誘導基因組不穩定性及參與鼻咽癌發生的機制 2013-2017年 280 萬元
    7.“973”課題:“致瘤病毒感染和致癌機制”,2011-2017年 170 萬元
    8.國家自然科學基金杰出青年基金(81025014)頭頸腫瘤 2011-2014年 200 萬元
    9.國家自然科學基金重點項目(30630068) 鼻咽癌早期診斷的基礎研究 2007-2010年140萬元  
    10.“863”計劃課題(2007AA02Z477)鼻咽癌早期診斷新方法研究 2007-2010年 230萬元

    【代表性論著】(*通信作者)
    1)Zhang H, Li Y, Wang HB, Zhang A, Chen ML, Fang ZX, Dong XD, Li SB, Du Y, Xiong D, He JY, Li MZ, Liu YM, Zhou AJ, Zhong Q, Zeng YX, Kieff E, Zhang ZQ, Gewurz BE, Zhao B*, Zeng MS*, Ephrin receptor A2 is an epithelial cell receptor for EBV entry. Nat Microbiol, 2017. (In Press)
    2)Zhong Q, Liu Z, Lin ZR, Hu ZD, Yuan L, Liu YM, Zhou AJ, Xu LH, Hu LJ, Wang ZF, Guan XY, Hao JJ, Lui VWY, Guo L, Mai HQ, Chen MY, Han F, Xia YF, Grandis JR, Zhang X*, Zeng MS*, The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res, 2017. 
    3)Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS*, Zhang Z*, TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat Commun, 2017. 8(1): p. 945 
    4)Chen XX, Zhong Q, Liu Y, Yan SM, Chen ZH, Jin SZ, Xia TL, Li RY, Zhou AJ, Su Z, Huang YH, Huang QT, Huang LY, Zhang X, Zhao YN, Yun JP, Wu QL, Lin DX, Bai F*, Zeng MS*, Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing. Nat Commun, 2017. 8(1): p. 524. 
    5)Tang LQ, Zhang H, Li Y, Zhang A, Chen ML, Li SB, Mai HQ*, Zeng MS*, A Sponsored Supplement to Science:Precision medicine in China,Chapter 2, Precision medicine for nasopharyngeal carcinoma, Science, 2016.12.23, 24~27
    6)Hua WF, Zhong Q, Xia TL, Chen Q, Zhang MY, Zhou AJ, Tu ZW, Qu C, Li MZ, Xia YF, Wang HY, Xie D, Claret FX, Song EW, Zeng MS*, RBM24 suppresses cancer progression by upregulating miR-25 to target MALAT1 in nasopharyngeal carcinoma. Cell Death Dis, 2016. 7(9): p. e2352 
    7)Hu LJ, Lin ZR, Wu YH, Dong JQ, Zhao B, Cheng YB, Huang PY, Xu LH, Xia TL, Xiong D, Wang HB, Li MZ, Guo L, Kieff E, Zeng YX, Zhong Q*, Zeng MS*, Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing. Front Med, 2016. 10(1): p. 61-75.
    8)Li RC, Du Y, Zeng QY, Tang LQ, Zhang H, Li Y, Liu WL, Zhong Q, Zeng MS*, Huang XM*, Antibodies Against Epstein-Barr Virus Glycoprotein gp42 for the Diagnosis of Nasopharyngeal Carcinoma. Clin Lab, 2016. 62(4): p. 553-61.
    9)Tang LQ, Li CF, Li J, Chen WH, Chen QY, Yuan LX, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Zhang L, Guo SS, Liu LT, Guo L, Wu YS, Luo DH, Huang PY, Mo HY, Xiang YQ, Sun R, Chen MY, Hua YJ, Lv X, Wang L, Zhao C, Cao KJ, Qian CN, Guo X, Zeng YX, Mai HQ*, Zeng MS*, Establishment and Validation of Prognostic Nomograms for Endemic Nasopharyngeal Carcinoma. J Natl Cancer Inst, 2016. 108(1).
    10)Liu ZH, Hu JL, Liang JZ, Zhou AJ, Li MZ, Yan SM, Zhang X, Gao S, Chen L, Zhong Q*, Zeng MS*, Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression. Cell Death Dis, 2015. 6: p. e1920.
    11)Xiong D, Du Y, Wang HB, Zhao B, Zhang H, Li Y, Hu LJ, Cao JY, Zhong Q, Liu WL, Li MZ, Zhu XF, Tsao SW, Hutt-Fletcher LM, Song E, Zeng YX, Kieff E*, Zeng MS*, Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A, 2015. 112(35): p. 11036-41.
    12)Wang HB, Zhang H, Zhang JP, Li Y, Zhao B, Feng GK, Du Y, Xiong D, Zhong Q, Liu WL, Du H, Li MZ, Huang WL, Tsao SW, Hutt-Fletcher L, Zeng YX, Kieff E, Zeng MS*, Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat Commun, 2015. 6: p. 6240.
    13)Tang LQ, Hu DP, Chen QY, Zhang L, Lai XP, He Y, Xu YX, Wen SH, Peng YT, Chen WH, Guo SS, Liu LT, Qian CN, Guo X, Zeng MS*, Mai HQ*, Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. PLoS One, 2015. 10(4): p. e0122965.
    14)Ni C, Chen Y, Zeng M (co-first author), Pei R, Du Y, Tang L, Wang M, Hu Y, Zhu H, He M, Wei X, Wang S, Ning X, Wang M, Wang J, Ma L, Chen X, Sun Q, Tang H, Wang Y, Wang X*, In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. Cell Res, 2015. 25(7): p. 785-800.
    15)Zong D, Yin L, Zhong Q, Guo WJ, Xu JH, Jiang N, Lin ZR, Li MZ, Han P, Xu L, He X*, Zeng MS*. ZNF 488 Enhances the Invasion and Tumorigenesis in Nasopharyngeal Carcinoma via the Wnt Signaling Pathway Involving Epithelial Mesenchymal Transition. Cancer Res Treat. 2015 Mar 12. doi: 10.4143/crt.2014.311.
    16)Han P, Lin ZR, Xu LH, Zhong Q, Zhu XF, Liang FY, Cai Q, Huang XM*, Zeng MS*, Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma. Mol Med Rep, 2015. 12(1): p. 401-9.
    17)Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, Xu YX, Hu DP, Wen SH, Peng YT, Chen WH, Liu H, Guo SS, Liu LT, Li J, Zhang JP, Guo L, Zhao C, Cao KJ, Qian CN, Zeng YX, Guo X, Mai HQ*, Zeng MS*, High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. Int J Radiat Oncol Biol Phys, 2015. 91(2): p. 325-36.
    18)Feng GK, Liu RB, Zhang MQ, Ye XX, Zhong Q, Xia YF, Li MZ, Wang J, Song EW, Zhang X*, Wu ZZ*, Zeng MS*, SPECT and near-infrared fluorescence imaging of breast cancer with a neuropilin-1-targeting peptide. J Control Release, 2014. 192: p. 236-42.
    19)Yuan L, Liu ZH, Lin ZR, Xu LH, Zhong Q*, Zeng MS*, Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma. Cancer Biol Ther, 2014. 15(12): p. 1613-21. 
    20)Zhang JP, Zhang H, Wang HB, Li YX, Liu GH, Xing S, Li MZ, Zeng MS*, Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma. J Transl Med, 2014. 12: p. 222 
    21)Zou QF, Du JK, Zhang H, Wang HB, Hu ZD, Chen SP, Du Y, Li MZ, Xie D, Zou J, Sun HD, Pu JX, Zeng MS* Anti-tumour activity of longikaurin A (LK-A), a novel natural diterpenoid, in nasopharyngeal carcinoma. J Transl Med, 2013. 11: p. 200 
    22)Wang HB, Liu GH, Zhang H, Xing S, Hu LJ, Zhao WF, Xie B, Li MZ, Zeng BH, Li Y, Zeng MS*, Sp1 and c-Myc regulate transcription of BMI1 in nasopharyngeal carcinoma. FEBS J, 2013. 280(12): p. 2929-44.
    23)Xu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, Liu WS, Cao JY, Zhang Y, Feng QS, Chen LZ, Li MZ, Liu ZW, Liu Q, Hong MH, Shugart YY, Zeng YX, Zeng MS*, Jia WH*, An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst, 2012. 104(18): p. 1396-410.
    24)Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, Song LB, Zeng MS*, Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer, 2011. 10(1): p. 10.
    25)Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, Liang Y, Xiong D, Guan S, Guo BH, Mai HQ, Chen QY, Zhang X, Li MZ, Shao JY, Qian CN, Xia YF, Song LB, Zeng YX, Zeng MS*, Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog, 2010. 6(6): p. e1000940.
    26)Cao JY, Liu L, Chen SP, Zhang X, Mi YJ, Liu ZG, Li MZ, Zhang H, Qian CN, Shao JY, Fu LW, Xia YF*, Zeng MS*, Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Mol Cancer, 2010. 9: p. 237.
    27)Dong J, Zeng BH, Xu LH, Wang JY, Li MZ, Zeng MS*, Liu WL *, Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med, 2010. 8: p. 81.
    28)Liu WL, Guo XZ, Zhang LJ, Wang JY, Zhang G, Guan S, Chen YM, Kong QL, Xu LH, Li MZ, Song LB, Zeng MS*, Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma. BMC Cancer, 2010. 10: p. 467.
    29)Guo BH, Zhang X, Zhang HZ, Lin HL, Feng Y, Shao JY, Huang WL, Kung HF, Zeng MS*, Low expression of Mel-18 predicts poor prognosis in patients with breast cancer. Ann Oncol, 2010. 21(12): p. 2361-9.
    30)Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, Li MZ, Zhang L, Kang TB, Fu LW, Huang WL, Xia YF, Tsao SW, Li M, Band V, Band H, Shi QH, Zeng YX, Zeng MS*, The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest, 2009. 119(12): p. 3626-36.
    31)Qin ZK, Yang JA, Ye YL, Zhang X, Xu LH, Zhou FJ, Han H, Liu ZW, Song LB, Zeng MS*, Expression of Bmi-1 is a prognostic marker in bladder cancer. BMC Cancer, 2009. 9: p. 61.
    32)Liu WL, Zhang G, Wang JY, Cao JY, Guo XZ, Xu LH, Li MZ, Song LB, Huang WL, Zeng MS*, Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun, 2008. 375(3): p. 440-5.
    33)Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS*, Prognostic relevance of Centromere protein H expression in esophageal carcinoma. BMC Cancer, 2008. 8: p. 233.
    34)Liu JH, Song LB, Zhang X, Guo BH, Feng Y, Li XX, Liao WT, Zeng MS*, Huang KH*, Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol, 2008. 97(3): p. 267-72 
    35)Liao WT, Song LB, Zhang HZ, Zhang X, Zhang L, Liu WL, Feng Y, Guo BH, Mai HQ, Cao SM, Li MZ, Qin HD, Zeng YX, Zeng MS*, Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res, 2007. 13(2 Pt 1): p. 508-14.
    36)Song LB, Zeng MS*, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V, Zeng YX, Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res, 2006. 66(12): p. 6225-32.
    37)Song LB, Liao WT, Mai HQ, Zhang HZ, Zhang L, Li MZ, Hou JH, Fu LW, Huang WL, Zeng YX, Zeng MS*, The clinical significance of twist expression in nasopharyngeal carcinoma. Cancer Lett, 2006. 242(2): p. 258-65.
    38)Jiang RC, Qin HD, Zeng MS(co-first author), Huang W, Feng BJ, Zhang F, Chen HK, Jia WH, Chen LZ, Feng QS, Zhang RH, Yu XJ, Zheng MZ, Zeng YX*, A functional variant in the transcriptional regulatory region of gene LOC344967 cosegregates with disease phenotype in familial nasopharyngeal carcinoma. Cancer Res, 2006. 66(2): p. 693-700.
    39)Zeng M, Zhang Y, Bhat I, Wazer DE, Band H, Band V*, The human kallikrein 10 promoter contains a functional retinoid response element. Biol Chem, 2006. 387(6): p. 741-7.
    40)Zeng MS, Li DJ, Liu QL, Song LB, Li MZ, Zhang RH, Yu XJ, Wang HM, Ernberg I, Zeng YX*, Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol, 2005. 79(24): p. 15323-30.
    41)Zeng M, Kumar A, Meng G, Gao Q, Dimri G, Wazer D, Band H, Band V*, Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J Biol Chem, 2002. 277(47): p. 45611-8.

    【主要國際學術會議】
    1.大會秘書長:The 6th Guangzhou International Symposium on Oncology, Nov.30-Dec.2, 2017,  Guangzhou, China
    2.特邀會議報告:Title: Cellular Factors in Epstein-Barr Virus Infection of Nasopharyngeal Epithelial Cells, 17th International Symposium on EBV and associated diseases. August 8 to 12, 2016, Zurich, Switzerland
    3.特邀會議報告:Title, NPC, an Epithelial Cancer: Immortalization and Tumorigenesis. NPC Gordon Research Conference, June 26-July 1, 2016, Hong Kong, China
    4.大會秘書長:The 5th Guangzhou International Symposium on Oncology, Dec.1-3, 2016,  Guangzhou, China
    5.特邀會議報告:Title, NPC, The predictive /prognostic biomarker for nasopharyngeal carcinoma. Nasopharyngeal Carcinoma Symposium Biannual Meeting, Jun 3-6, 2015, Yogyakarta, Indonesia
    6.大會秘書長:The 4th Guangzhou International Symposium on Oncology, Nov.5-7, 2015,  Guangzhou, China
    7.特邀會議報告:Title:NRP1 interacts with gB and mediates EBV infection of nasopharyngeal epithelial cells. International Forum for hepesvirus, associated disease and antiviral development. Nov 15-16, 2014  Guangzhou,China
    8.特邀會議報告:Title:Epstein-Barr virus infection in nasopharyngeal carcinoma:Role in pathogenesis and therapeutic implications.Sino-German cancer,viruses and immune response symposium. May 13-14, 2014  Guangzhou,China
    9.受邀參加主題為“代謝異常與腫瘤”的第106期雙清論壇  2014.1.7
    10.特邀報告:Nebraska大學特邀中美學術會議  2014.6.11
    11.特邀報告:中德學術研討會  2014.5.12
    12.受邀參加主題為“上皮細胞可塑性與腫瘤發生發展”的第83期雙清論壇  2012.10.31
    13.特邀報告:2012 international Congress on Oncogenic Herpesviruses and Associated Diseases  2012.8.1-8.4
    14.特邀報告:2012年全國腫瘤分子標志學術大會與國際腫瘤轉化醫學論壇暨第七屆中國青年腫瘤專家論壇   2012.7.20-7.23
    15.主題發言:中美頭頸腫瘤研討會2012.1.6-1.7
    16.主題發言:中-法腫瘤學研討會 2011.11.25-11.26
    17.主題發言: 17th International Charles Heidelberger Symposium on Cancer Research At The Fourth Military Medical University In Xi’an   2011.6.5-6.10
    18.分會報告: The Second Guangzhou International Symposium on Oncology 2011.5.18-5.20
    19.參會并大會發言:Title: Epstein-Barr Virus-Encoded LMP2A Induces EMT and Increases Side Population of Stem-like Cancer Cells in Nasopharyngeal Carcinoma. The 14th Biennial Conference of The International  Association for Research on Epstein-Barr Virus and Associated Diseases  Sept 5-72th ,2010, Birmingham,UK
    20.特邀會議報告:Title:Bmi-1, a polycomb group protein, plays an essential role in tumorigenesis and metastasis. 68th Annual Meeting of the Japanese Cancer Association, Oct 1-3, 2009. Yokohama
    21.特邀會議報告:Title:Bmi-1, a polycomb group protein, plays an essential role in tumorigenesis and metastasis. 2009年6月19日  國際癌癥生物研討會, 國立中山大學生物醫學研究所, 高雄
    22.主辦并大會報告:The 13th Biennial Conference of The International Association for Research on Epstein - Barr virus and Associated Diseases Nov. 7th— Nov.10th ,2008, 廣州。參會代表300余人,包括國外及港臺代表 220余人。
    23.特邀大會報告: Title:Cellular and Viral Oncogenes in NP Cell Transformation. AACR International Conference (Infection and Cancer: Biology, Therapeutics, and Prevention) Dec. 5th-7th, 2008. Hongkong
    24.特邀會議報告Title: The mechanism of EBV infection to nasopharyngeal epithelial cells.  The 7th Sino-Japan Joint Conference for Cancer Research December 7th~10th, 2008 Guangzhou, China
    25.參會并大會發言:Title: Bmi-1 is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial Cells.  The 12th Biennial Conference of The International  Association for Research on Epstein-Barr Virus and Associated Diseases  July 8-12th ,2006, Boston
    26.參會并大會發言:Title: Full-length sequencing and analysis of a EBV genome from a Cantonese NPC patient. East-West Symposium on NPC,2005,Toronto, Cannada

    【學術兼職】
    1. 國際EB病毒及相關疾病協會理事會成員(2010-)
    2. 國家自然科學基金委員會專家評審組成員
    3. 中國抗癌協會理事
    4. 中國抗癌協會腫瘤標志專業委員會副主任委員
    5. 中國抗癌協會腫瘤轉移專業委員會委員
    6. 廣東省預防醫學會病毒學專業委員會常務委員
    7. 《癌癥》雜志常務篇委
    8、廣東省抗癌協會轉移委員會主任委員
    9.Scientific Data雜志編委(2014-)


    更新日期:2018年1月24日
訪客通道
員工通道
關注腫瘤醫院
留言建議 ×